Vera Therapeutics VERA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's investing cash flow?
- Vera Therapeutics (VERA) reported investing cash flow of -$137.82M in Q1 2026.
- How has Vera Therapeutics's investing cash flow changed year-over-year?
- Vera Therapeutics's investing cash flow decreased by 999.8% year-over-year, from $15.32M to -$137.82M.
- What is the long-term trend for Vera Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Vera Therapeutics's investing cash flow has grown at a 579.8% compound annual growth rate (CAGR), from -$4.2M to $194.29M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.